Related references
Note: Only part of the references are listed.Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
Pauline du Rusquec et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold et al.
PHARMACOLOGICAL RESEARCH (2019)
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine- refractory differentiated thyroid cancer
Makoto Tahara et al.
EUROPEAN JOURNAL OF CANCER (2019)
Treatment-Emergent Hypertension and Efficacy in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT)
Lori J. Wirth et al.
CANCER (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
Koichi Suyama et al.
CANCER CONTROL (2018)
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Takayuki Kimura et al.
CANCER SCIENCE (2018)
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong et al.
ONCOTARGET (2017)
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes
Robert I. Haddad et al.
ENDOCRINE (2017)
NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells
Nobuhisa Takase et al.
CANCER LETTERS (2016)
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
K. M. Morrissey et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi et al.
IMMUNOTHERAPY (2016)
Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis
Chenjing Zhu et al.
ONCOTARGET (2016)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Share Paper
